Outstanding effectiveness of paclitaxel-based technologies for the treatment of femoropopliteal artery occlusive disease on the potential expense of increased late all-cause mortality? No reason to panic.

Thomas Zeller,Tanja Böhme,Ulrich Beschorner,Michel Mpj Reijnen,Elias Noory

doi:10.1024/0301-1526/a000778

Outstanding effectiveness of paclitaxel-based technologies for the treatment of femoropopliteal artery occlusive disease on the potential expense of increased late all-cause mortality? No reason to panic.

Thomas Zeller, Tanja Böhme + Show 3 more

https://doi.org/10.1024/0301-1526/a000778

Copy DOI

Export

Save

Cite

Journal: VASA. Zeitschrift fur Gefasskrankheiten	Publication Date: Mar 1, 2019
Citations: 8

Affiliation: Universitäts-Herzzentrum Freiburg-Bad Krozingen, Rijnstate Hospital, University of Twente

#Femoropopliteal Disease #Late Mortality #Treatment Of Disease #Femoropopliteal Artery Occlusive Disease #Late All-cause Mortality #Femoropopliteal Artery #Artery Occlusive Disease #Occlusive Disease #All-cause Mortality

Abstract
Full-Text
Similar Papers

Abstract

Listen

Outstanding effectiveness of paclitaxel-based technologies for the treatment of femoropopliteal artery occlusive disease on the potential expense of increased late all-cause mortality? No reason to panic.

Full Text

Published Version

Check institute access

Open DOI Link

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: VASA. Zeitschrift fur Gefasskrankheiten

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.

R Discovery Prime

Outstanding effectiveness of paclitaxel-based technologies for the treatment of femoropopliteal artery occlusive disease on the potential expense of increased late all-cause mortality? No reason to panic.